Device Trial Radar · NCT04984590
Early Feasibility Study Using IOPCL MAG to Improve Near Vision in ARMD Subjects
Last checked: Nov 20, 2026Latest source record: Jan 31, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
9
Actual
Start
Jan 21, 2022
Primary completion
Mar 20, 2024
Study completion Mar 20, 2024
Sponsor
- Lead sponsor
- OnPoint Vision IncNot on our public-company list
- Sponsor type
- Industry
- First posted
- Jul 30, 2021
Design
- Study type
- Interventional
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This early feasibility study aims to improve near vision in subjects 55 years or older who have a clinical diagnosis of Age-Related Macular Degeneration. Subjects must have previously been implanted with either the Alcon Model SN60WF or Model SA60AT intraocular lens at least 6-months prior to receiving the IOPCL (intraocular pseudophakic capsular lens). Subject will be followed for a period of 12-months.
Conditions
- Low Vision
- Age Related Macular Degeneration
Interventions
IOPCL AMD MAGDevice
The IOPCL MAG (intraocular pseudophakic capsular lens magnifier) consists of a 4.5 mm diameter optic. The central 1.8mm of the anterior surface has a power of 10.0 diopters. This IOPCL MAG will be implanted over an Alcon Model SN60WF or SA60AT intraocular lens to improve near vision.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Tilt of the PCIOL and IOPCL MAG ComplexTime frame: 12 Months
- IOPCL MAG DecentrationTime frame: 12 Months
- Uncorrected Near Visual Acuity at 14cm Change From Baseline (Letters) (≥ 75% Achieving ≥ 10 Letters)Time frame: 12 Months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Harvard Eye Associates
Laguna Hills, California
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.